Lessons from a literature review about the economic impact of drug treatment for six conditions;Réflexions sur un essai de mesure de l'impact du médicament: Les enseignements d'une revue bibliographique conduite sur six affections

Journal d'Economie Medicale

Volumn 19, Issue 1-2, 2001, Pages 113-124

  Sailly, J C ^a   Lebrun, T ^a  

^a CRESGE   (France)

Author keywords

Cost; Cost consequences; Drug treatment; Economic impact

Indexed keywords

ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIULCER AGENT; CARDIOVASCULAR AGENT; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEPRESSION; DRUG COST; DUODENUM ULCER; ECONOMIC ASPECT; HEALTH CARE COST; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 0035003483     PISSN: 02940736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. An economic evaluation of asthma in the United States
2. The economic costs of noninsulin-dependent diabetes mellitus
3. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)
4. Les répercussions fonctionnelles et en termes de recours aux soins de l'asthme chronique
5. Le coût du diabète en France
6. Type 2 diabetes: Incremental medical care costs during the first 8 years after diagnosis
7. Le coût des maladies coronariennes
8. Resource utilisation in the management of dyslipidaemia
9. The cost of duodenal ulcer disease in France : A macroeconomic inquire
10. Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer
11. The economic burden of depression in 1990
12. Coût et retentissement de la maladie d'Alzheimer en France: Une extrapolation des données de l'étude PAQUID
13. The US economic and social costs of Alzheimer's disease revisited
14. The economic burden of affective disorders
15. Advantages of high-dose inhaled budesonide
16. The episode-free day as a composite measure of effectiveness
17. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
18. Model of complications of NIDDM : II - Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia
19. The West of Scotland coronary prevention study : Economic benefit analysis of primary prevention with pravastatin
20. A reappraisal of economic evaluation of pharmaceuticals. Sciences or marketing ?
21. Pharmaceutical economy and the economic assessment of drugs in France
22. Cost of illness studies: Useful for health policy ?
23. The role of cost-effectiveness analysis in managed-care decisions
24. The role of economic evaluation in the pricing and reimbursement of medicine